RE:Holding longAll Thomas needed to say at the agm was that we expect phase 2 results in 2 months and this should start to open doors for financing and create interest in the stock. Instead he was talking about how they were looking for primarily safety and to a lesser degree efficacy. When I asked about whether or not we needed anything from Aspire, he went into the details of source data verification. I understand the need to clean and verify the data but it seems like a key piece of info is being left out, especially when Lacey says we need to sue to get our data back. We are being told 2 entirely different things. On one hand, we are being told, the lawsuit has no bearing on our ability to publish phase 2 and on the other hand it seems clear that we need to win against Aspire to complete the trial and finally see whether or not ACP works. We'll see in August, but I suspect that we won't see phase 2 results until legal is concluded and its anyones guess as to who can survive the costs of the lawsuits longer, Aspire or Hemostemix. No one is investing in this train wreck until some clarity is provided so for me, I think it's good phase 2 results in August or bankruptcy. Just my take on it. Lets hope my suspicions are incorrect. But if there are more delays in August instead of results, you can bet we aren't going anywhere until we somehow raise enough money to win against Aspire in court, which seems highly unlikely